The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2016 | Immunotherapy for multiple myeloma: current research avenues
Shaji Kumar, MD from the Mayo Clinic, Rochester, MN discusses the current research on immunotherapy in multiple myeloma (MM). The biggest advance so far is daratumumab according to Dr Kumar. Daratumumab is a monoclonal antibody targeting CD38 and its has been to shown to have high efficacy as a single agent and in combination with lenalidomide and bortezomib. Elotuzumab, which targets SLAMF7, has also been shown to be active in combination with bortezomib and pomalidomide. Dr Kumar further discusses CAR T-cell therapy, which is in early clinical development and has shown efficacy in leukemia with some reports that it might also be effective in myeloma. Finally, he talks about vaccination studies and checkpoint inhibitors.
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
